New York Magazine examines cancer drug pricing

Share this article:
New York Magazine examines cancer drug pricing
New York Magazine examines cancer drug pricing

In a story published online on October 20th, New York magazine took readers through the Memorial Sloan-Kettering/Zaltrap pricing battle with Leonard Saltz, one of the three oncologists who penned the op-ed in the New York Times which started it all and concluded with Sanofi/Regeneron slashing the price of then new breast cancer drug Zaltrap in half due to "market resistance."

The seven-page article online also quoted Hagop Kantarjian, head of the Department of Leukemia at the University of Texas's MD Anderson Cancer Center, who is currently campaigning against Gleevec, a leukemia treatment whose price has tripled since 2001.

Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.